禁食对18F-DCFPyL在前列腺癌病灶及已知高生理摄取组织中的摄取影响
研究纳入禁食至少6小时的50例患者与未禁食的50例患者,比较18F-DCFPyL在前列腺癌可疑病灶及正常组织中的SUVmax。可疑病灶摄取在两组间无差异,禁食组下颌下腺、肝脏和脾脏摄取显著高于非禁食组,绝对差异较小,禁食对诊断性能的影响可视为可忽略。
要点
- 禁食至少6小时与非禁食患者的前列腺癌可疑病灶18F-DCFPyL摄取无差异。
- 禁食组下颌下腺、肝脏和脾脏的18F-DCFPyL摄取显著高于非禁食组。
- 摄取绝对差异较小,禁食对诊断性能的影响可视为可忽略。
核心结论
- 禁食不显著影响18F-DCFPyL在可疑恶性病灶中的摄取,但导致高生理摄取组织的18F-DCFPyL摄取显著降低,绝对差异较小,对诊断性能的影响可视为可忽略。
研究设计与样本
- 研究纳入禁食至少6小时后再给予18F-DCFPyL的50例患者和未禁食的50例患者,比较前列腺癌特征性病灶及已知高生理摄取正常组织中的SUVmax。
主要发现
- 可疑病灶摄取在禁食组与非禁食组之间无差异。
- 下颌下腺、肝脏和脾脏的18F-DCFPyL摄取在禁食组显著高于非禁食组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the literature, a 4- to 6-h fast is recommended before a patient undergoes PET/CT with 2-(3-(1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid (18F-DCFPyL); however, a scientific underpinning for this recommendation is lacking. Therefore, we performed a study to determine the impact of fasting on 18F-DCFPyL uptake. Methods: The study included 50 patients who fasted at least 6 h before 18F-DCFPyL administration and 50 patients who did not. Activity (SUVmax) was measured in lesions characteristic of prostate cancer and in normal tissues known to express high physiologic uptake. Results: Uptake in suspected lesions did not differ between the cohorts. 18F-DCFPyL uptake in the submandibular gland, liver, and spleen was significantly higher in the fasting than the nonfasting cohort. Conclusion: Our data show that fasting does not significantly affect 18F-DCFPyL uptake in suspected malignant lesions but does result in significantly lower 18F-DCFPyL uptake in tissues with high physiologic uptake. The absolute differences in uptake were relatively small; therefore, the effects of fasting on the diagnostic performance can be considered negligible.
引用
- Wondergem M, van der Zant FM, Vlottes PW, et al. Effects of Fasting on 18F-DCFPyL Uptake in Prostate Cancer Lesions and Tissues with Known High Physiologic Uptake. J Nucl Med. 2018. PMID: 29496983. doi:10.2967/jnumed.117.207316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。